Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.56 |
| ▸ | CTSS | P25774 | 7/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995124 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL1992449 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL11086941 | 0.86 | CTSS (0.47) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL3186812 | 0.86 | CTSS (0.61) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL5742936 | 0.86 | CTSS (0.61) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL5740500 | 0.86 | CTSS (0.61) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL1998569 | 0.83 | KMT2A (0.47) | MAPTATM | |
| SCHEMBL1998567 | 0.83 | KMT2A (0.47) | MAPTATM | |
| SCHEMBL7273399 | 0.83 | GABRB1 (0.52) | CTSKCTSSCTSLCTSBGABRB1 | |
| SCHEMBL11852061 | 0.82 | CTSS (0.45) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | claimed |
| EP-0540606-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP plc (GB) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001695-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | claimed |
| US-4550162-A | Process for the manufacture of enol derivatives | CIBA-GEIGY CORPORATION (US) | 1985-10-29 | — | — | US | claimed |
| US-4526962-A | Cephalosporin derivatives | RHONE-POULENC SANTE (FR) | 1985-07-02 | — | — | US | claimed |
| US-4319027-A | Process for the manufacture of ceohem enol derivatives | CIBA-GEIGY CORPORATION (US) | 1982-03-09 | — | — | US | claimed |
| US-4301278-A | BY HYDROGENATION IN THE PRESENCE OF A CATALYST | CIBA-GEIGY CORPORATION (US) | 1981-11-17 | — | — | US | claimed |
| US-4255328-A | CEPHALOSPORINS | CIBA-GEIGY CORPORATION (US) | 1981-03-10 | — | — | US | claimed |
| US-4147864-A | Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | claimed |
| US-4110533-A | PROCESS FOR THE MANUFACTURE OF ENOL DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | claimed |
| US-10654807-B2 | Toll-like receptor 8 agonists | THE UNIVERSITY OF KANSAS (US) | 2020-05-19 | — | — | US | disclosed |
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | THE UNIVERSITY OF KANSAS | 2016-12-01 | — | — | US | disclosed |
| US-4001226-A | 3-(SUBSTITUTED)CARBONYLAMINO CEPHEM DERIVATIVES | ELI LILLY AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3941781-A | Preparation of 3-alkylthiomethyl cephalosporins | ELI LILLY AND COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
| US-3932465-A | ANTIBIOTIC | CIBA-GEIGY CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654807-B2 | Toll-like receptor 8 agonists | TLR8, TLR7, TLR1 | CTSK 4673/4885CTSS 4320/4885CTSL 3343/4885 |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | TLR8, TLR7, TLR1 | CTSK 4673/4885CTSS 4320/4885CTSL 3343/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | CTSK 343/4885CTSS 210/4885CTSL 365/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | CTSK 4461/4885CTSS 3941/4885CTSL 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.